Two cases of alopecia areata treated with ruxolitinib: a discussion of ideal dosing and laboratory monitoring.
Two cases of alopecia areata treated with ruxolitinib: a discussion of ideal dosing and laboratory monitoring.
复制标题
DOI：
10.1111/ijd.13598
复制
发表时间：
2017-08
影响因子：
3.6
通讯作者：
Garza LA
中科院分区：
文献类型：
--
作者：
Vandiver A;Girardi N;Alhariri J;Garza LA
斑秃是一种相对常见的状况，影响患者看到在社区皮肤科诊所。2014年的一项研究表明，JAK1/JAK2抑制剂ruxolitinib可短期治疗脱发，但关于社区环境中健康个体长期使用ruxolitinib的信息很少。1例慢性斑秃患者和1例急性发性脱发患者口服鲁索利替尼治疗1年多。经过一年的治疗，两名患者都经历了持续的，近乎完全的再生，没有血液学或其他并发症。口服鲁索利替尼有效、安全治疗两例女性脱发。对于社区中无反应性脱发的病例，应考虑使用Ruxolitinib。
Alopecia areata is a relatively common condition affecting patients seen in community dermatology clinics. A 2014 study implicated the JAK1/JAK2 inhibitor, ruxolitinib in short-term treatment of alopecia, however little information exists about the long-term use in otherwise healthy individuals in the community setting. A patient with chronic alopecia areata and a patient with acute onset alopecia universalis were treated with oral ruxolitinib for over a year. Both patients experienced sustained, near-complete regrowth without hematologic or other complications after one year of treatment. Oral ruxolitinib effectively and safely treated alopecia in two women. Ruxolitinib should be considered for cases of unresponsive alopecia in the community.
影响因子：
82.9
作者：
通讯作者：
--
影响因子：
10.1
作者：
Al-Ali, Haifa Kathrin;Griesshammer, Martin;Vannucchi, Alessandro M.
通讯作者：
Vannucchi, Alessandro M.